

ASX RELEASE

25 June 2021

Annual General Meeting to be held Friday 27 August 2021

Amplia Therapeutics Limited (ASX: ATX) ('Amplia' or the 'Company') advises that its Annual General Meeting in respect of its financial year ended 31 March 2021 is to be held on Friday 27 August 2021.

Details of the meeting venue and other meeting arrangements will be confirmed at a later date.

In accordance with ASX Listing Rule 14.3 nominations for the election of Directors must be received by the Company not later than Friday 9 July 2021.

This ASX announcement was approved and authorised for release by the Company Secretary.

- End -

For Further Information

Andrew J. Cooke
andrew@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and fibrosis and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. In addition, the company is pursuing the potential of its FAK inhibitors in pulmonary fibrosis.